RxDoctor Payments Data

Hugo Jimenez, MD

General Practice · Greenacres, FLNPI 1598129173

Payments from drug & device makers

$1,754in general payments, 2019–2025

Across 89 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$646
  • Boehringer Ingelheim$333
  • Novo Nordisk$283
  • Lilly USA, LLC$262
  • Bayer$106
  • Pfizer$56
  • plus $69 from 2 others

What the payments were for

  • Food & beverage$1,74399%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca33$646
Boehringer Ingelheim18$333
Novo Nordisk15$283
Lilly USA, LLC12$262
Bayer4$106
Pfizer3$56
GSK3$48
Exact Sciences1$21

How this compares

$1,754 in reported general payments places this provider in the 85th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$13,628
Medicare patients
29
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin411$535,252
FarxigaDapagliflozin Propanediol226$274,407
OzempicSemaglutide196$245,363
RybelsusSemaglutide57$121,446
MounjaroTirzepatide65$109,853
Breztri AerosphereBudesonide/Glycopyr/Formoterol97$104,292
EliquisApixaban80$89,108
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$78,869
EntrestoSacubitril/Valsartan50$65,462
XareltoRivaroxaban74$62,350
LinzessLinaclotide46$37,389
VascepaIcosapent Ethyl55$37,193
Tresiba Flextouch U-100Insulin Degludec61$34,611
JanuviaSitagliptin Phosphate21$23,663
JanumetSitagliptin Phos/Metformin Hcl22$22,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$333$535,252411 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$646$388,793350 claims
Novo NordiskOzempic, Rybelsus, Novolog$283$369,730266 claims
Lilly USA, LLCMounjaro$262$109,85365 claims
PfizerEliquis$56$89,10880 claims
GSKTrelegy Ellipta$48$78,86969 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,901 general practice providers in Florida.

Other general practice in Greenacres

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →